Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study.

IF 2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Jill Maggs, Gregory S Sawicki, Callie Bacon, Emma McWilliams, Dana Yablon, Benjamin Ertman, Liam Sweeney, Jennifer L Butcher, Robin S Everhart, Michelle Prickett, Christopher Siracusa, Alex H Gifford, Nicole Mayer-Hamblett, David P Nichols, Andrea Goodman, Tia Woo, Kristin A Riekert
{"title":"Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study.","authors":"Jill Maggs, Gregory S Sawicki, Callie Bacon, Emma McWilliams, Dana Yablon, Benjamin Ertman, Liam Sweeney, Jennifer L Butcher, Robin S Everhart, Michelle Prickett, Christopher Siracusa, Alex H Gifford, Nicole Mayer-Hamblett, David P Nichols, Andrea Goodman, Tia Woo, Kristin A Riekert","doi":"10.1016/j.cct.2024.107752","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>As people with cystic fibrosis (pwCF) live longer due to the breakthrough drug elexacaftor-tezacaftor-ivacaftor (ETI), they have questioned whether other CF therapies could be safely discontinued. SIMPLIFY was the first prospective, randomized trial to evaluate non-inferiority of discontinuing versus continuing two therapies. The QUEST (Qualitative Understanding of Experiences in the SIMPLIFY Trial) study was conducted to understand experiences of pwCF enrolled in SIMPLIFY, including why they joined, perceptions of randomization, decision-making around study withdrawal, and considerations for future discontinuation studies.</p><p><strong>Methods: </strong>QUEST enrolled SIMPLIFY participants 14 years or older stable on ETI and caregivers of the 14-17 year-olds. Interviews were audio-recorded, transcribed, and coded. A phenomenological approach was used to inductively develop codes with no a priori hypotheses; identified themes were then organized around current research and recruitment literature.</p><p><strong>Results: </strong>114 interviews were completed (68 adults, 23 teenagers, and 23 caregivers). Among pwCF, median age was 27.8 years, 49 % were female and 80 % had participated in research before SIMPLIFY. Five themes were identified: ((Gul and Ali, 2010 [1]) Experience with SIMPLIFY randomization, CFF Patient Registry Annual Data Report [Internet] (2017) [2] Trust, CFF Patient Registry Annual Data Report [Internet] (2022) [3] Altruism, Goss et al. (2008) [4] Perceived personal benefits, and (Goss et al., 2002 [5]) Perceived risks and protocol burden.</p><p><strong>Conclusion: </strong>QUEST findings highlight how a long-standing culture of research and thoughtful protocol design contributed to SIMPLIFY's successful recruitment and retention. This included understanding the importance of remaining in the trial despite not being randomized to their preferred treatment assignment. Using patient-centered approaches to select research questions, design a protocol to minimize participant barriers, and frame recruitment materials messaging contribute to successful research participation.</p>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":" ","pages":"107752"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cct.2024.107752","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: As people with cystic fibrosis (pwCF) live longer due to the breakthrough drug elexacaftor-tezacaftor-ivacaftor (ETI), they have questioned whether other CF therapies could be safely discontinued. SIMPLIFY was the first prospective, randomized trial to evaluate non-inferiority of discontinuing versus continuing two therapies. The QUEST (Qualitative Understanding of Experiences in the SIMPLIFY Trial) study was conducted to understand experiences of pwCF enrolled in SIMPLIFY, including why they joined, perceptions of randomization, decision-making around study withdrawal, and considerations for future discontinuation studies.

Methods: QUEST enrolled SIMPLIFY participants 14 years or older stable on ETI and caregivers of the 14-17 year-olds. Interviews were audio-recorded, transcribed, and coded. A phenomenological approach was used to inductively develop codes with no a priori hypotheses; identified themes were then organized around current research and recruitment literature.

Results: 114 interviews were completed (68 adults, 23 teenagers, and 23 caregivers). Among pwCF, median age was 27.8 years, 49 % were female and 80 % had participated in research before SIMPLIFY. Five themes were identified: ((Gul and Ali, 2010 [1]) Experience with SIMPLIFY randomization, CFF Patient Registry Annual Data Report [Internet] (2017) [2] Trust, CFF Patient Registry Annual Data Report [Internet] (2022) [3] Altruism, Goss et al. (2008) [4] Perceived personal benefits, and (Goss et al., 2002 [5]) Perceived risks and protocol burden.

Conclusion: QUEST findings highlight how a long-standing culture of research and thoughtful protocol design contributed to SIMPLIFY's successful recruitment and retention. This included understanding the importance of remaining in the trial despite not being randomized to their preferred treatment assignment. Using patient-centered approaches to select research questions, design a protocol to minimize participant barriers, and frame recruitment materials messaging contribute to successful research participation.

定性了解囊性纤维化患者在停止治疗试验中的经历:QUEST 研究。
背景:由于突破性药物 elexacaftor-tezacaftor-ivacaftor (ETI)的问世,囊性纤维化患者(pwCF)的寿命延长了,他们对是否可以安全停用其他 CF 疗法提出了质疑。SIMPLIFY 是首个前瞻性随机试验,旨在评估停用两种疗法与继续使用两种疗法的非劣效性。QUEST(Qualitative Understanding of Experiences in the SIMPLIFY Trial)研究旨在了解加入 SIMPLIFY 的儿童患者的经历,包括他们加入的原因、对随机化的看法、围绕研究退出的决策以及未来停药研究的考虑因素:QUEST招募了SIMPLIFY的14岁或14岁以上稳定接受ETI的参与者以及14-17岁儿童的照顾者。对访谈进行了录音、转录和编码。在没有先验假设的情况下,采用现象学方法归纳出编码;然后根据当前的研究和招募文献对确定的主题进行整理:共完成了 114 次访谈(68 名成人、23 名青少年和 23 名护理人员)。在儿童和青少年中,年龄中位数为 27.8 岁,49% 为女性,80% 在 SIMPLIFY 之前参与过研究。研究确定了五个主题:(Gul和Ali,2010 [1])SIMPLIFY随机化的经验,CFF患者注册年度数据报告[互联网](2017)[2]信任,CFF患者注册年度数据报告[互联网](2022)[3]利他主义,Goss等人(2008)[4]感知到的个人利益,以及(Goss等人,2002 [5])感知到的风险和协议负担:QUEST 的研究结果突显了长期的研究文化和周到的方案设计是如何帮助 SIMPLIFY 成功招募和留住人才的。这包括理解在未被随机分配到首选治疗方案的情况下仍留在试验中的重要性。使用以患者为中心的方法来选择研究问题、设计方案以最大限度地减少参与者的障碍,以及编写招募材料信息,都有助于成功参与研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.50%
发文量
281
审稿时长
44 days
期刊介绍: Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信